News

Recent News About Hesperos and Human-on-a-Chip Technology

NIH Director Features HESPEROS BODY-ON-A-CHIP DEVICE for predicting CANCER DRUG RESPONSES

By Hesperos | September 30, 2019 | Comments Off on NIH Director Features HESPEROS BODY-ON-A-CHIP DEVICE for predicting CANCER DRUG RESPONSES

Dr. Francis Collins, director of The National Institutes of Health, recently featured Hesperos technology on his blog. In the post, Dr. Collins reviews a published study where Hesperos researchers investigated and treated several cancer lines with … Read More

Hesperos Human-on-a-Chip Technology Awarded First Phase of $3.8 Million Milestone-based NIH Grant to Study Opiate Overdoses in Collaboration With UCF

By Hesperos | September 26, 2019 | Comments Off on Hesperos Human-on-a-Chip Technology Awarded First Phase of $3.8 Million Milestone-based NIH Grant to Study Opiate Overdoses in Collaboration With UCF
Hesperos

Hesperos, Inc., (www.hesperosinc.com) announced today the University of Central Florida (UCF) received the first phase of a $3.8 million milestone-based National Institutes of Health (NIH) grant for research involving the company’s human-on-a-chip system. “We are grateful … Read More

Human-on-a-Chip Predicts In Vivo Results Based on In Vitro Model for the first time

By Hesperos | July 3, 2019 | Comments Off on Human-on-a-Chip Predicts In Vivo Results Based on In Vitro Model for the first time
human-on-a-chip

HUMAN-ON-A-CHIP PREDICTS IN VIVO RESULTS BASED ON IN VITRO MODEL FOR THE FIRST TIME Hesperos’ integrated heart-liver Human-on-a-Chip® shown to correctly determine cardiotoxic mechanisms preclinically and replicate results seen in in vivo studies (ORLANDO, Fla.) — Hesperos Inc., pioneers of the … Read More

Human-on-a-chip Model Enables Simultaneous Testing of Cancer Drug Efficacy and Off-Target Toxicity to Enable Determination of Therapeutic Index

By Hesperos | June 19, 2019 | Comments Off on Human-on-a-chip Model Enables Simultaneous Testing of Cancer Drug Efficacy and Off-Target Toxicity to Enable Determination of Therapeutic Index
hesperos

In vitro multi-organ system by Hesperos, Inc. realistically replicates the responses of cancer treatments and has potential to inform treatment decisions. ORLANDO, FLA – June 19, 2019 — A reconfigurable “body-on-a-chip” model could transform drug development … Read More

Hesperos’ Models Under Consideration to Address Opiod Crisis

By Hesperos | March 18, 2019 | Comments Off on Hesperos’ Models Under Consideration to Address Opiod Crisis
hesperos

The interest in our human-on-a-chip model continues to grow.  Last week we brought our systems to the National Center for Translational Science (NCATS) at the NIH in Washington, D.C. to perform a real-time demo using live … Read More

HESPEROS’ multi-organ “Human-on-a-Chip” System Found Effective for Long-Term Toxicology Testing

By Hesperos | March 1, 2019 | Comments Off on HESPEROS’ multi-organ “Human-on-a-Chip” System Found Effective for Long-Term Toxicology Testing
Hesperos

HESPEROS’ MULTI-ORGAN “HUMAN-ON-A-CHIP” SYSTEM FOUND EFFECTIVE FOR LONG-TERM TOXICOLOGY TESTING Collaboration between L’Oreal, Hesperos and UCF results in further reduction in reliance on animal testing in drug and cosmetics development (ORLANDO, Fla.) The replacement of animals … Read More

Hesperos at NCATS-NASA State-of-the-Science Meeting

By Hesperos | January 2, 2019 | Comments Off on Hesperos at NCATS-NASA State-of-the-Science Meeting
slas

HESPEROS AT NCATS-NASA STATE-OF-THE-SCIENCE MEETING We’ve been forging new frontiers with our human-on-a-chip multi-organ models—could the next one take us into space?  Last month, we traveled to Washington, DC, to attend a workshop with officials from … Read More